ELCC 2016 | Phase 2 trial of chemotherapy plus gefitinib as first-line treatment for lung adenocarcinoma
Giorgio Scagliotti
At the 6th European Lung Cancer Conference (ELCC), held in Geneva, Switzerland, from 13–16 April 2016, Giorgio Scagliotti, MD, PhD, from the University of Turin, Turin, Italy, discusses a phase 2 trial evaluating the combination of chemotherapy and gefitinib, a tyrosine kinase inhibitor of epidermal growth factor receptor (EGFR), as first-line treatment for patients with advanced lung adenocarcinoma and activating EGFR mutations.
Similar topics
Related videos

BTOG 2020: what to expect
Sanjay Popat

Pharmacy perspective: pembrolizumab monotherapy 6 weekly dosing
Rob Duncombe

Minimizing the risk of steroid-induced hyperglycemia in NSCLC patients receiving immunotherapy
Islam Elkonaissi

SB8: a bevacizumab biosimilar for NSCLC
Martin Reck

The immunotherapy NSCLC revolution
Solange Peters
More from Giorgio Scagliotti